BCL2 and cancer: Researchers showed that MET reduced migration and invasion of cancer cells in tamoxifen-resistant breast cancer cells and in combination with tamoxifen synergistically inhibited proliferation of ER-positive breast cancer via Bax/Bcl-2 and AMPK/mTOR/p70S6K pathways (33, 34).